Skip to content

Jason M Tucciarone

2 papers in the library · 9 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

The American journal of psychiatry June 1, 2026 Jason M Tucciarone, Igor D. Bandeira, Christine Blasey et al. 5 citations

Ketamine rapidly reduces suicidal ideation in major depressive disorder (MDD), but its effects are transient. Preclinical and clinical studies suggest that ketamine's antidepressant and antisuicidal effects may be partly mediated by mu-opioid receptor (MOR) modulation. The authors investigated the efficacy and safety of low-dose sublingual buprenorphine, a partial MOR agonist, as a follow-on...

Methodological considerations for interpreting ketamine-naltrexone trials in depression

The International Journal of Neuropsychopharmacology October 1, 2025 Igor D. Bandeira, Luke A. Jelen, Jason M Tucciarone et al. 4 citations

Igor D Bandeira, MD, PhD, Luke A Jelen, MD, PhD, Jason M Tucciarone, MD, PhD, Boris D Heifets, MD, PhD, Carolyn I Rodriguez, MD, PhD, Alan F Schatzberg, MD